Updates in Therapies Counteracting Tissue Factor Pathway Inhibition in Patients with Hemophilia: Recognizing Developments and Clinical Context in Therapy
February 1, 2023
February 1, 2024
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Med Learning Group and Ultimate Medical Academy/Complete Conference Management (CCM).
This activity is supported by an educational grant from Novo Nordisk, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is intended to meet the educational needs of hematologists, HTC nurses, and other allied health care professionals who treat patients with hemophilia.
With a focus on emerging anti-tissue factor pathway inhibition therapies, this enduring activity addresses developments in hemophilia management which are an important priority for clinicians seeking to improve clinical outcomes in their patients with hemophilia A and B, including patients with evidence of inhibitors to conventional factor VIII and factor IX replacement therapies.
Upon the completion of this program, attendees should be able to:
- Evaluate the burden of hemophilia A and B, as well as unmet needs in management of patients with inhibitors.
- Recognize the role of tissue factor and tissue factor pathway inhibition in the pathophysiology of hemophilia.
- Evaluate the latest data on anti-tissue factor pathway inhibition therapies for management of hemophilia.
- Review best practices for engaging in multidisciplinary management of patients with hemophilia in consideration of novel therapies in development.
Maya Bloomberg, MSN, APRN, FNP-BC
Hematology Nurse Practitioner
University of Miami Hemophilia Treatment Center
Allison P. Wheeler, MD, MSCI
Assistant Professor in Pathology and Pediatrics
Vanderbilt University Medical Center
Hemophilia and Bleeding Disorders Patient Liaison
Optum Infusion Pharmacy
Director of Education, Innovative Therapies
National Hemophilia Foundation
New York, NY
Physician Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation
Med Learning Group designates this enduring activity for a maximum of 1.0 credit AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Credit Designation
Purpose: This program would be beneficial for nurses involved in the care of patients with hemophilia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE Accreditation Statement
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Conflict of Interest
|Allison P. Wheeler||Discloses that she has received consulting fees from Novo Nordisk, HEMA Biologics, Takeda, Pfizer, and Octapharma|
|Maya Bloomberg, MSN, APRN, FNP-BC||Discloses that she has received consulting fees from Bayer, Genentech, Novartis, Novo Nordisk, Octapharma, Sanofi, and Takeda. She has also used a speaker’s bureau for Genentech, Bayer, Sanofi, and Novo Nordisk.|
|Jessica Ruiz||Has nothing to disclose|
|Brendan Hayes||Has nothing to disclose|
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Cindy Lampner, MSLIS, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CME credit for enduring this activity. To receive CME/CNE credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are science based.This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com. Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/"
Americans with Disabilities Act
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.